NCT04453241View on ClinicalTrials.gov

Immunogenicity and Safety Study of NBP615 in Healthy Female

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 22, 2018

Primary Completion Date

December 30, 2019

Study Completion Date

December 30, 2019

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

NBP615

Intramuscular injection, 0.5ml

BIOLOGICAL

Gardasil

Intramuscular injection, 0.5ml

Trial Locations (1)

13494

SK Bioscience, Gyeonggi-do

All Listed Sponsors
lead

SK Bioscience Co., Ltd.

INDUSTRY

NCT04453241 - Immunogenicity and Safety Study of NBP615 in Healthy Female | Biotech Hunter | Biotech Hunter